Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Blood (2019) 134 (Supplement_1): 1082.

https://doi.org/10.1182/blood-2019-122665

Published: 2019

Journal Articles

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Lucrecia Yanez San Segundo, MD PhD, Noemi Fernandez Escalada, MD, Arancha Bermúdez, MD, Guillermo Martín Sánchez, MD, Sara García Avila, MD, Mónica López Duarte, MD, Mercedes Colorado, MD, Iñigo Romon, MD PhD, Carlos Richard, MD, Enrique M. Ocio, MD PhD

Blood (2019) 134 (Supplement_1): 5655.

https://doi.org/10.1182/blood-2019-130731

Published: 2019

Journal Articles

Elevated FANCA Expression Marks a Worse Prognosis in Chronic Lymphocytic Leukemia. Evidence of a New Role of FANCA in the Stability of p53 By a Neddylation-Related Mechanism

Carlos Pipaon, PhD, Sara Bravo Navas, Iñigo Romon, MD PhD, Eulogio Conde, MD PhD, Lucrecia Yanez San Segundo, MD PhD

Blood (2018) 132 (Supplement 1): 5541.

https://doi.org/10.1182/blood-2018-99-113398

Published: 2018

Journal Articles

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Cristina Fernández Martínez, Arancha Bermúdez, MD, Sara García Ávila, MD, Borja San Pedro, Almudena Cabero Martínez, MD, Lucrecia Yáñez, MD PhD, Mónica López Duarte, Mercedes Colorado, MD, Sonia González de Villambrosia, MD, Joan Manuel Mora, MD, Yolanda Gonzalez Romero, MD, David Gomez, MD, Sara Fenandez Luis, MD, Irati Ormazabal, MD, Andrés Insunza, Iñigo Romon, MD PhD, Jose Luis Arroyo, MD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2018-99-114124

Published: 2018

Journal Articles

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Joan Manuel Mora, MD, Arancha Bermúdez, MD, Miguel Angel Cortés, MD, Yolanda González Romero, MD, Mercedes Colorado, MD, Cristina Fernández Martínez, MD, Almudena Cabero Martínez, MD, David Gómez, MD, Sara Fernández Luis, MD, Sara García Ávila, MD, Lucrecia Yáñez, MD PhD, Irati Ormazabal, MD, Guillermo Martín Sánchez, MD, Jose Luis Arroyo, MD, Javier Núñez, MD, Iñigo Romón, MD PhD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2018-99-118664

Published: 2018

Journal Articles

Differences of Antithymocyte Globulin (ATG) Side Effects during Allogeneic Stem Cell Transplantation

Lucrecia Yañez San Segundo, MD PhD, Brenda Lopez Pereira, MD, Maria Aranzazu Bermudez, MD, Andres Insunza, Iñigo Romon, MD PhD, Carlos Richard, MD, Eulogio Conde, MD PhD

Blood (2015) 126 (23): 5449.

https://doi.org/10.1182/blood.V126.23.5449.5449

Published: 2015

NARROW

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Elevated FANCA Expression Marks a Worse Prognosis in Chronic Lymphocytic Leukemia. Evidence of a New Role of FANCA in the Stability of p53 By a Neddylation-Related Mechanism

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Differences of Antithymocyte Globulin (ATG) Side Effects during Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Elevated FANCA Expression Marks a Worse Prognosis in Chronic Lymphocytic Leukemia. Evidence of a New Role of FANCA in the Stability of p53 By a Neddylation-Related Mechanism

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Differences of Antithymocyte Globulin (ATG) Side Effects during Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only